Compounding Retreat and French Reimbursement Set the Stage for Novo Nordisk’s ADA Data

France will begin covering the cost of Novo Nordisk’s Wegovy for severe obesity from June 15, 2026, granting the Danish drugmaker access to one of Europe’s largest healthcare markets. But the move comes with a catch: Eli Lilly’s Mounjaro has been placed in the same reimbursement basket, meaning the broader GLP-1 pie grows but Novo Nordisk gets no exclusive slice. The dual reimbursement, announced this week, covers both FlexTouch and KwikPen formulations at 65% for outpatient use, with hospitals also able to procure the drugs.

Eligibility is tightly drawn. Adults must have a body mass index of at least 40 kg/m² without comorbidities, or at least 35 kg/m² with a weight-related condition. Initial prescriptions can be written only by specialised obesity centres or affiliated endocrinologists, and a French health insurance document is required for reimbursement. For Novo Nordisk, the development lowers the access barrier for patients and may give physicians greater confidence in prescribing Wegovy. Yet the competitive symmetry with Lilly means commercial success will hinge on prescription habits, adherence and pricing dynamics.

That pricing pressure is being reinforced by events across the Atlantic. Jefferies reiterated its “Hold” rating on the stock this week, keeping a 270 Danish krone price target that sits below the current share price. The bank’s main point of discussion was the shrinking market for compounded GLP-1 preparations – custom-made drugs that flooded the US during supply shortages and at their peak accounted for roughly one-third of all GLP-1 volume. That share has now fallen to about 15%, and Jefferies expects it could halve again next year as regulatory and legal risks mount. A smaller compounding market supports demand for branded Wegovy and Ozempic, but persistent price competition still caps the upside for Novo Nordisk’s shares.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

The stock itself closed Friday at €39.05, edging down 0.06% on the day but finishing the week with a 0.81% gain. Over the past month the equity has climbed 13.06%, though it remains 12.59% lower year-to-date and has tumbled 35.73% over the past twelve months. Technical indicators point to a neutral posture: the shares trade roughly 7% below their 200-day moving average, and the relative strength index sits near 48, a level that signals neither overbought nor oversold conditions.

Behind the scenes, Novo Nordisk has been buying back its own stock. Since February 4, the company has repurchased approximately 17 million B-shares at an average price of 262 Danish kroner, for a total transaction value of about 4.5 billion kroner. The overall buyback programme runs until February 2027 and can reach up to 15 billion kroner. While the repurchase provides a steady capital return, it is not enough on its own to sway analysts who remain sceptical about the outlook for GLP-1 pricing.

All eyes are now turning to New Orleans, where Novo Nordisk will present 40 abstracts at the American Diabetes Association congress from June 5 to 8, 2026. A dedicated R&D event is scheduled for June 7. The highlight will be phase 3 data for CagriSema in type 2 diabetes, along with phase 2 results for zenagamtide and further semaglutide analyses from Ozempic and Wegovy. These readouts carry extra weight because the company’s outlook has already been revised upwards for 2026: Novo Nordisk now expects adjusted revenue and operating profit to decline by 4% to 12%, a narrower range than previously anticipated. In the most recent quarter, adjusted revenues excluding the US 340B effect fell 4% at constant exchange rates, while obesity product revenues rose 22%.

The tension between reimbursement wins and pricing headwinds leaves the stock in a delicate spot. France has improved access, but Lilly shares the same door. Jefferies is waiting for concrete evidence that branded GLP-1 volumes can grow sustainably without deeper price concessions. Strong CagriSema data on June 7 would bolster the reimbursement story; weak signals would refocus attention on the competitive and pricing risks that have already dragged the stock down by more than a third over the past year.

Ad

Novo Nordisk Stock: New Analysis - 30 May

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

en | DK0062498333 | COMPOUNDING | boerse | 69450131 |